Diagnostic Testing of Common Sexually Transmitted Infections
This document governs reimbursement and testing guidance for diagnostic laboratory testing of common sexually transmitted infections (STIs) for Blue Cross Blue Shield - Oklahoma members. It affects providers ordering and billing for laboratory-based STI tests.
Reimbursement information revised for clarity and literature review updated.
Added policy statement that when an individual meets conditions for both chlamydia and gonorrhea, multitarget PCR testing (targets limited to C. trachomatis and N. gonorrhoeae) may be reimbursable.
References revised; some added and others removed.
Coverage Criteria
Multitarget PCR for chlamydia and gonorrhea
Coverage stance noted in policy update history:
Coding
| No codes listed |
Provider Actions and Billing Guidance
Multitarget PCR reimbursement allowance for dual indications
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.